Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Beyond research, the CDC plays a transformative role in shaping Malaysia’s clinical trial ecosystem — training investigators, ...

One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics ' ( VKTX 0.32%) stock in ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...

Europe’s last manufacturer of ingredients for some vital antibiotics is closing its biggest domestic factory and shifting ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

With more than 3,500 students, Brockton High School is the biggest high school in Massachusetts and become known in recent years for chronic understaffing. Mirroring the nickname of its sports teams, ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

A recent study from Ixlayer indicates patients are looking for pharma companies to do more to improve upon their current DTC offerings.